MX2021003241A - Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. - Google Patents
Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.Info
- Publication number
- MX2021003241A MX2021003241A MX2021003241A MX2021003241A MX2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- intermediates
- manufacturing process
- crystalline form
- tosylate salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748628P | 2018-10-22 | 2018-10-22 | |
| PCT/IB2019/058940 WO2020084435A1 (en) | 2018-10-22 | 2019-10-21 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003241A true MX2021003241A (es) | 2021-05-12 |
Family
ID=68343187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003241A MX2021003241A (es) | 2018-10-22 | 2019-10-21 | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12116368B2 (https=) |
| EP (1) | EP3870584A1 (https=) |
| JP (1) | JP6944496B2 (https=) |
| KR (1) | KR102629132B1 (https=) |
| CN (1) | CN112888691B (https=) |
| AR (1) | AR116797A1 (https=) |
| AU (1) | AU2019363840B2 (https=) |
| BR (1) | BR112021007568A2 (https=) |
| CA (1) | CA3059000C (https=) |
| IL (1) | IL282446B2 (https=) |
| MX (1) | MX2021003241A (https=) |
| SG (1) | SG11202103667QA (https=) |
| TW (1) | TWI729530B (https=) |
| WO (1) | WO2020084435A1 (https=) |
| ZA (1) | ZA202101735B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020338043B2 (en) | 2019-08-26 | 2025-12-18 | Chemwerth, Inc. | Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors |
| KR20220123271A (ko) * | 2019-12-31 | 2022-09-06 | 화이자 알앤디 유케이 리미티드 | 1-((2S,5R)-5-((7H-피롤로[2,3-d]피리미딘-4-일)아미노)-2-메틸피페리딘-1-일)프로프-2-엔-1-온의 안정한 즉시 방출형 정제 및 캡슐 제형 |
| CN113121539A (zh) * | 2019-12-31 | 2021-07-16 | 江苏艾立康医药科技有限公司 | 一种pf06651600的制备方法 |
| CN111732591B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 l-酒石酸盐，晶型及其制备方法 |
| CN111620880B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 dl-酒石酸盐，晶型及其制备方法 |
| CN114835715B (zh) * | 2020-06-15 | 2024-04-05 | 江苏艾立康医药科技有限公司 | Pf-06651600马来酸盐及其制备方法 |
| WO2022012587A1 (zh) * | 2020-07-14 | 2022-01-20 | 苏州晶云药物科技股份有限公司 | 丙烯酮类化合物的丙二酸盐晶型及其制备方法 |
| KR102473645B1 (ko) * | 2020-08-28 | 2022-12-05 | (주)부흥산업사 | (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법 |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| WO2025144783A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Methods of synthesizing substituted pyrrolopyrimidine compounds |
| WO2025146702A1 (en) * | 2024-01-03 | 2025-07-10 | Msn Laboratories Private Limited, R&D Center | Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid |
| WO2025219875A1 (en) * | 2024-04-17 | 2025-10-23 | Alembic Pharmaceuticals Limited | Solid forms of ritlecitinib or its salts |
| CN118420493B (zh) * | 2024-04-24 | 2026-04-14 | 山东福长药业有限公司 | 一种2,5-二取代氨基己酸酯的制备方法及使用其制备利特昔替尼的方法 |
| WO2025244944A1 (en) * | 2024-05-20 | 2025-11-27 | Opna Bio SA | Crystal forms of an agent |
| WO2025257773A1 (en) | 2024-06-11 | 2025-12-18 | Assia Chemical Industries Ltd. | Processes for the preparation of ritlecitinib and intermediates thereof |
| CN119060059B (zh) * | 2024-08-21 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种甲苯磺酸利特昔替尼的制备工艺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9911365A (pt) | 1998-06-19 | 2001-03-13 | Pfizer Prod Inc | Compostos pirrolo[2,3-d]pirimidina |
| MX368464B (es) * | 2013-12-05 | 2019-10-02 | Pfizer | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo. |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105859721B (zh) * | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
-
2019
- 2019-10-16 JP JP2019189151A patent/JP6944496B2/ja active Active
- 2019-10-17 CA CA3059000A patent/CA3059000C/en active Active
- 2019-10-17 TW TW108137470A patent/TWI729530B/zh active
- 2019-10-21 KR KR1020217015125A patent/KR102629132B1/ko active Active
- 2019-10-21 CN CN201980069164.0A patent/CN112888691B/zh active Active
- 2019-10-21 AU AU2019363840A patent/AU2019363840B2/en active Active
- 2019-10-21 US US17/286,018 patent/US12116368B2/en active Active
- 2019-10-21 SG SG11202103667QA patent/SG11202103667QA/en unknown
- 2019-10-21 MX MX2021003241A patent/MX2021003241A/es unknown
- 2019-10-21 WO PCT/IB2019/058940 patent/WO2020084435A1/en not_active Ceased
- 2019-10-21 EP EP19794259.2A patent/EP3870584A1/en active Pending
- 2019-10-21 IL IL282446A patent/IL282446B2/en unknown
- 2019-10-21 BR BR112021007568-2A patent/BR112021007568A2/pt unknown
- 2019-10-22 AR ARP190103015A patent/AR116797A1/es unknown
-
2021
- 2021-03-15 ZA ZA2021/01735A patent/ZA202101735B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3059000A1 (en) | 2020-04-22 |
| US20210387989A1 (en) | 2021-12-16 |
| SG11202103667QA (en) | 2021-05-28 |
| TWI729530B (zh) | 2021-06-01 |
| EP3870584A1 (en) | 2021-09-01 |
| AR116797A1 (es) | 2021-06-16 |
| AU2019363840A1 (en) | 2021-04-01 |
| ZA202101735B (en) | 2022-07-27 |
| JP6944496B2 (ja) | 2021-10-06 |
| KR20210080468A (ko) | 2021-06-30 |
| US12116368B2 (en) | 2024-10-15 |
| BR112021007568A2 (pt) | 2021-07-27 |
| KR102629132B1 (ko) | 2024-01-29 |
| TW202033525A (zh) | 2020-09-16 |
| CN112888691A (zh) | 2021-06-01 |
| IL282446B1 (en) | 2024-02-01 |
| JP2020066629A (ja) | 2020-04-30 |
| WO2020084435A1 (en) | 2020-04-30 |
| IL282446B2 (en) | 2024-06-01 |
| IL282446A (en) | 2021-06-30 |
| AU2019363840B2 (en) | 2021-12-09 |
| CA3059000C (en) | 2026-04-14 |
| CN112888691B (zh) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003241A (es) | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. | |
| MX2021012849A (es) | Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak. | |
| MX2024005335A (es) | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. | |
| UY37781A (es) | Proceso para la preparación de pirazolo[1,5-a] pirimidinas y sales de las mismas | |
| MXPA04005401A (es) | Compuestos cristalinos novedosos. | |
| ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
| CU20120155A7 (es) | SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO | |
| PE20191499A1 (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| MX2017006412A (es) | Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida. | |
| BRPI0611863A2 (pt) | composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo | |
| UY36176A (es) | Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida | |
| PA8516501A1 (es) | Profarmacos de pirimidinas inhibitorias de la replicacion de hiv | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
| NZ737725A (en) | Crystalline forms of a bruton’s tyrosine kinase inhibitor | |
| BR112017016487A2 (pt) | 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia | |
| SG193245A1 (en) | Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer | |
| BR112017026173A2 (pt) | Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo | |
| MX2018004332A (es) | Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas. | |
| MX2020013896A (es) | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. | |
| CO2018012431A2 (es) | Comprimidos de disgregación oral | |
| CR9966A (es) | Acido 1-(1-(2-etoxietil-3-etil-7-(4-metilpiridin-2-ilamino)-1h-pirazolo[4,3-d]pirimidin-5-il)piperidina-4-carboxilico y las sales del mismo. | |
| MX2019007452A (es) | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. | |
| MX386181B (es) | Formas cristalinas de un inhibidor de quinasa janus | |
| CL2020003227A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak. |